Accordingly, many literatures have indicated that targeted down-regulation of prosurvival Bcl-2 proteins is an pertinent strategy for apoptosis-based therapeutics in CLL (Billard, 2012; Fegan and Pepper, 2013). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.